EGFR L861Q

2/ @LeXiuning @MDAndersonNews on EGFR mutations: ▪️EGFR mutations ~10-20% NSCLC pts in Europe/N America, & up to 50% of patients in Asia ▪️Exon 19 del & exon 21 L858R most common (~85-90%) ▪️🔑 Most frequent uncommon mutations to know: G719X, S768I, L861Q, & exon 20 insertions (@esinghimd)

Retrospective analysis of osimertinib in 50 pts with atypical #EGFR NSCLC in #JTOCRR. Median time to d/c 17.2m for L861Q, 7.8m for G719X, 1.5m for exon 20 insertion. Afatinib is the approved standard for atypical; amivantamab and mobocertinib for ex20ins. https://t.co/kQiqpEJYTZ (@StephenVLiu)

🚨🚨 Check out our latest collaboration: #UNICORN: UNcommon EGFR mutations: International Case series on efficacy of #osimertinib in 1st liNe J Bair et al. ▶️N=60, G719X L861Q & T790M ▶️ORR 61%, mOS 24.5m. compound EGFR+ did better @EGFRResisters #lcsm https://t.co/7CqrcJpiXr (@Latinamd)

In this multi-center, retrospective study @JTOonline for uncommon EGFR mutation (n=60), osimertinib demonstrated an ORR of 61% (44% for denovo T790M, 47% for G719X ORR & 80% for L861Q) Md PFS 9.5 mo Md DOR 17.4 mo & Md OS of 24.5 mo #LCSM @OncoAlert https://t.co/XxvURqgISg (@dipeshuprety4)

Osimertinib in NSCLC w uncommon EGFR mutns @JTOonline: - 60pt retrosp study, overall ORR 66% - G719X ORR 47% mPFS 8.8m mDOR 9.1m - L861Q ORR 80% mPFS 16m mDOR 16m - de novo T790M ORR 44% mPFS 12.7m mDOR 46.2m ?⬇️ORR T790M than expected, important study https://t.co/B3kpq7AKbR (@DrJNaidoo)

Retrospective report @Annals_Oncology from the national Network of Genomic Medicine in Germany describes 856 NSCLC cases with atypical #EGFR mutations. Includes G719X, S7681, L861Q, exon 20 insertions and rare point mutations with clinical outcomes. #LCSM https://t.co/2benHuhrA7 (@StephenVLiu)

#L861Q #exon21 #egfr #LCSM Currently on Osi 180mg + Abraxane (4th line in one year) Can you move backwards to never before used Afantinib? @DevikaDasMD @Tony_Calles @HenningWillers @LeciaSequist @StephenVLiu (@mindyjoyphoto)

#OncoAlert Characterization of #EGFR L861Q mutation @JTOonline @IASLC. L861Q was ~ 3% of EGFR mutations (30% had compound mutations, usually in exon 18). Retrospectively, better outcomes with 2nd gen EGFR TKIs compared to 1st or 3rd generation. #LCSM https://t.co/NW4ZJD0Zmy (@StephenVLiu)

#OncoAlert In vitro work showed #EGFR L861Q relies on asymmetric dimerization with prominent HER2 phosphorylation (thus, greater efficacy with pan-HER TKIs). Potential for greater personalization of therapy here. Great work by @michael_offin @HelenaYu923 @MLadanyi #LCSM (@StephenVLiu)

@JackWestMD Patient question. Is there any data for pulse dose osimertinib for a oatient with egfr L861Q mutant nscca w brain Mets through 80 mg daily of tagrisso, already treated w gamma knife and whole brain? Would adding ramucirimab or avastin be a consideration? Thanks (@andrea20372113)